H. Lundbeck A/S
http://www.lundbeck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From H. Lundbeck A/S
Lundbeck Pursues Brintellix Infringement Charges In India
Lundbeck seeks to ward off Alembic and Hetero over alleged patent infringing activity pertaining to its depression therapy vortioxetine in India. The product is seen as one of the key drivers of growth in 2021 for the Danish company, which has settled infringement proceedings with over half a dozen generic opponents so far in the US.
Analyst Insight: Top 2021 Health Care Trends On Display At RSNA
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Lundbeck Highlights Vyepti Potential, But Company's 2021 Outlook Cautious
Lundbeck is focused on the global launch of its new migraine therapy Vyepti in the coming years, and the development of additional indications, as its reported a 4% increase in revenues in 2020 which were within its pre-pandemic guidance.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abide Therapeutics Inc.
- Alder Biopharmaceuticals, Inc.
- Chelsea Therapeutics International, Ltd.
- Lundbeck La Jolla Research Center
- Lundbeck Seattle Biopharmaceuticals
- Ovation Pharmaceuticals, Inc
- Saegis Pharmaceuticals, Inc.